Answers are grounded in this paper and cite their sources.
Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) is subject to clinically significant drug-drug interactions with strong enzyme inducers such as rifampicin due to markedly reduced drug exposure and potential development of resistance. However, real-world evidence on managing this interaction remains scarce. We report a person with HIV, virologically suppressed on LAI CAB/RPV, who developed an orthopaedic implant-associated infection requiring 10-week rifampicin-containing therapy for its antibiofilm activity. Further LAI CAB/RPV injections were withheld, and oral tenofovir disoproxil fumarate/emtricitabine once daily plus dolutegravir 50 mg twice daily was initiated. This regimen was continued until 3 weeks after rifampicin discontinuation; afterwards, dolutegravir was reduced to once daily. LAI CAB/RPV was restarted 5 weeks after rifampicin withdrawal; oral antiretroviral therapy was discontinued. Serial therapeutic drug monitoring (TDM) showed a rapid decline in plasma CAB and RPV concentrations from day 8 after rifampicin initiation, with both drugs falling below the efficacy thresholds by day 10. In contrast, tenofovir and dolutegravir concentrations remained within the therapeutic range during rifampicin co-administration, whereas twice-daily dolutegravir concentrations exceeded the therapeutic range 3 weeks after rifampicin discontinuation. HIV RNA remained undetectable throughout follow-up. This case confirms the clinically relevant interaction between rifampicin and LAI CAB/RPV, as illustrated by the rapid decline in residual CAB and RPV plasma concentrations following rifampicin initiation. Temporary substitution with a recommended first-line oral antiretroviral regimen maintained adequate drug exposure, was well tolerated and preserved virological suppression throughout rifampicin treatment. TDM allowed to characterize the interaction and may support individualized management in selected complex clinical situations.
No takes yet. Share an insight, caveat, or question.
Ciullini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: